Tokyo, Japan (June 25, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Commission (EC) has granted Marketing Authorisation for LIXIANA® ...

Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according to NICE.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once ...

A spokesman for Daiichi Sankyo indicated that the daily listed cost of Lixiana is £2.10, although he told pharmaphorum that "costs around the country may vary because of negotiated procurement ...

Daiichi Sankyo Company, Limited (hereafter, "Daiichi Sankyo") today announced results from ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study ...

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ELIMINATE-AF study. The multinational, randomised phase 3b study will ...

Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is ...

Daiichi Sankyo’s Lixiana has become the fourth novel oral anticoagulant (NOAC) to be granted approval in the EU. The European Commission has given the green light for Lixiana (edoxaban) to be used to ...

Daiichi Sankyo has been traveling a rocky road with its new-age anticoagulant Lixiana, but the company's load may be getting lighter. The Japanese pharma has tapped Merck to launch the drug in ...

The FINANCIAL -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) on April 27 announced that the European Committee for Medicinal ...

Commission's approval of LIXIANA, which means physicians and patients may benefit from a new treatment option to effectively manage these debilitating and life-threatening conditions," said Jan van ...

The FINANCIAL — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) on June 25 announced that the European Commission (EC) has granted Marketing Authorisation for LIXIANA (edoxaban), an ...